Cabometyx (cabozantinib tablet)

Consistent with the longer doubling time, PDES were more resistant to doxorubicin, etoposide and vincristine and ionising radiation (p < 0.0001) than cell lines. PDES were sensitive to mTKIs (cabozantinib, lenvatinib, and regorafenib), and trabectedin. The response of PDES to drugs in vitro reflects the clinical experience of patients. Models incorporating PDES cells may positively contribute to the preclinical pipeline.

P3, N=450, Not yet recruiting, Merck Sharp & Dohme LLC

P2, N=314, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

Subsequent biopsies at metastatic sites revealed adenocarcinoma consistent with a pancreatic primary tumor. We hypothesize that the immune features of UCOGC, including increased PD-1 and PD-L1 expression and tumor-infiltrating lymphocytes, may have contributed to the effectiveness of this combination immunotherapy regimen in this patient's response.

P1/2, N=10, Terminated, Genenta Science | The decision to terminate the study was not based on any safety concerns. Benefit-risk profile of IP unchanged.

P1, N=8, Active, not recruiting, National Cancer Institute (NCI) | N=18 --> 8 | Trial completion date: Nov 2025 --> Feb 2027

Drug-gene mapping revealed candidates spanning already in clinical trials for HNC (e.g. Afatinib, Cabozantinib, Dasatinib, Brigatinib, Lenvatinib, Capivasertib, Erdafitinib) and emerging or repurposing candidates (Amuvatinib, XL765 (Voxtalisib), Golotimod, Artenimol, Quercetin, and Acetylsalicylic Acid), offering opportunities for precision repurposing...These included targeted therapies such as Fostamatinib, Nintedanib, Brigatinib, Regorafenib, and Lenvatinib, as well as emerging compounds like Artenimol, Quercetin, and Acetylsalicylic Acid (Aspirin). Through a combination of genomic analysis, network expansion, and literature validation, the GARD pipeline offers a powerful way to accelerate personalized cancer treatments while reducing cost and development time.

Despite extensive prior treatment, patients experienced clinical benefit from TT, particularly VEGFR-TKIs, after progression on belzutifan. These findings support the feasibility of sequencing TT following belzutifan-based regimens in advanced ccRCC, and highlight the need to further define optimal therapeutic sequencing strategies.

P3, N=718, Not yet recruiting, SWOG Cancer Research Network

P=N/A, N=150, Recruiting, Ipsen | Not yet recruiting --> Recruiting

P1/2, N=28, Terminated, John Rieth | Trial completion date: Dec 2026 --> Oct 2025 | Active, not recruiting --> Terminated; Study was terminated early due to changes in the treatment of melanoma

Through integrated multi-omics analysis, we established that oxidative stress pathways may drive pNET progression through a coordinated mechanism involving metabolic reprogramming (via BCL2L1 and PHGDH downregulation), immune microenvironment remodeling (through altered dendritic cell and NK cell function), and complex regulatory networks. BCL2L1 and PHGDH represent potential diagnostic biomarkers and candidate therapeutic targets that require experimental validation, providing new directions for precision medicine in pNET.